Alert

Simulations Plus Inc. (SLP)

NasdaqGS: SLP · Real-Time Price · USD

18.38

+0.02 (0.11%)

At close: Aug 18, 2026, 10:39 AM

0.11% (1D)

Bid	13.22
Market Cap	371.73M
Revenue (ttm)	82.06M
Net Income (ttm)	8.11M
Beta	1.33
EPS (ttm)	0.4
PE Ratio (ttm)	45.95
Forward PE	20.83
P/B (ttm)	2.67
P/S (ttm)	4.53
Earnings Date	Oct 29, 2026

Ask	23.61
Volume	39,339
Avg. Volume (20D)	430,151
Open	18.40
Previous Close	18.36
Day's Range	18.38 - 18.41
52-Week Range	11.09 - 21.01
Analyst	n/a
Price Target	17.25 (-6.15%)
Dividends	n/a
Ex-Dividend Date	Jul 29, 2024

About SLP

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulati...

[Read more]

Industry Health Information Services

Sector Healthcare

IPO Date Jun 18, 1997

Employees 212

Stock Exchange NasdaqGS

Ticker Symbol SLP

Website https://www.simulations-plus.com

Full Company Profile

Financial Performance

In 2025, Simulations Plus's revenue was 79.18M, an increase of 13.09% compared to the previous year's 70.01M. Earnings were -64.72M, a decrease of -750.17%.

Financial Statements

Analyst Forecast

According to 2 analyst ratings, the average rating for SLP stock is "null". The 12-month stock price forecast is 17.25, which is downside of 6.15% from the latest price.

Stock Forecasts

Earnings Surprise

Simulations Plus has released their quarterly earnings on Jul 9, 2026:

Revenue of $21.89M misses estimates by $0, with 7.48% YoY growth.

EPS of 0.3 exceeds estimates by 0.07, with -33.33% YoY decline.

Next Earnings Release

Simulations Plus Inc. is scheduled to release its earnings on Oct 29, 2026, after market closes.
Analysts project revenue of ... Upgrade

News

1 month ago · Simply Wall St.

Certara (CERT) Stock Sees Fair Value Edges Lower As Analysts Trim Targets

Certara’s updated analyst model now carries a slightly lower fair value price target of US$7.48, compared with the prior US$7.62, reflecting only a modest adjustment. This small move aligns with recen...